Lupin plans to launch new generic drugs in US market by end of FY13

01 Feb 2013 Evaluate

Lupin, India’s fourth-largest drug-maker by sales is planning to launch three-four new generic drugs in its key US market by end of FY13. So far, the company has launched six products in this fiscal in the United States, which generates about 42% of its total formulation sales.

The drug-maker earlier reported a forecast-beating 42.6% rise in quarterly net profit to Rs 335 crore. 

The company, on consolidated basis, reported 42.61% rise in its net profit at Rs 335.23 crore for the quarter ended December 31, 2012 as compared to Rs 235.06 crore for the same quarter in the previous year. Total income of the company increased by 38.71% at Rs 2527.57 crore for quarter under review as compared to Rs 1822.24 crore for the quarter ended December 31, 2011.

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×